United States· US:71335-2400_38984dde-4201-4bd1-9a7c-44537f91be8c
Bupropion hydrochloride
A bupropion product containing bupropion hydrochloride, registered in United States by Bryant Ranch Prepack. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Bupropion is registered in 13 of 19 countries.
Countries holding a registration under ATC N06AX12 (bupropion), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Bupropion · ATC N06AX12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of bupropion costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), the median price runs from $0.10 in United States to $1.25 in Switzerland — a ×12 gap.
- United States: $0.10 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Bupropion · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$1.25
- IT Italy$0.90
- US United States$0.10 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Bupropion hydrochloride
- Manufacturer
- Bryant Ranch Prepack
- Country
- United States (US)
- ATC code
- N06AX12
- ATC class
- Bupropion
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 6
- ndc11713352400160 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-1)
- ndc117133524002180 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-2)
- ndc11713352400330 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-3)
- ndc11713352400490 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-4)
- ndc117133524005120 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-5)
- ndc11713352400628 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2400-6)
Regulatory notes
Interactions
808 interactions on record for bupropion.
Graded by severity as the source publishes them — 230 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bupropion · interactions on record
808 records
- 230 severe
- 217 moderate
- 4 minor
- 316 info
Most severe, free to view
- MetoclopramideA03FA01severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
41 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N06AX12
Bupropion, as other registers publish it.
- PolandBucidarRanbaxy (Poland) Sp. z o.o.
- PolandBucidarRanbaxy (Poland) Sp. z o.o.
- CzechiaBUPROPION +PHARMA+pharma arzneimittel gmbh, Graz
- CzechiaBUPROPION +PHARMA+pharma arzneimittel gmbh, Graz
- CzechiaBUPROPION +PHARMA+pharma arzneimittel gmbh, Graz
- CzechiaBUPROPION +PHARMA+pharma arzneimittel gmbh, Graz
- PolandBupropion AccordAccord Healthcare Polska Sp. z o.o.
- FinlandBupropion AccordAccord Healthcare B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f40222c9-7107-48e8-a153-7027f40e4593 GET /v1/drugs/f40222c9-7107-48e8-a153-7027f40e4593?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "ZG7E5POY8O",
"rxcui": "203204",
"inchikey": "HEYVINCGKDONRU-UHFFFAOYSA-N",
"display_name": "BUPROPION HYDROCHLORIDE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "ORAL",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 3
},
"spl_meta": {
"cefaaa17-f79a-4ba6-8f97-a59f60e07b75": {
"match": "brand_token",
"title": "BUPROPION HYDROCHLORIDE (XL) (BUPROPION HYDROCHLORIDE) TABLET, FILM COATED, EXTENDED RELEASE [BRYANT RANCH PREPACK]",
"spl_version": "105",
"published_date": "2026-06-01"
}
},
"productid": "71335-2400_38984dde-4201-4bd1-9a7c-44537f91be8c",
"productndc": "71335-2400",
"dosage_form": "TABLET, EXTENDED RELEASE",
"orange_book": {
"appl_no": "216800",
"products": [
{
"rs": false,
"rld": false,
"te_code": "AB1",
"strength": "100MG",
"product_no": "001",
"approval_date": "May 31, 2023"
},
{
"rs": false,
"rld": false,
"te_code": "AB1",
"strength": "150MG",
"product_no": "002",
"approval_date": "May 31, 2023"
},
{
"rs": false,
"rld": false,
"te_code": "AB1",
"strength": "200MG",
"product_no": "003",
"approval_date": "May 31, 2023"
}
],
"appl_type": "A"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "BUPROPION HYDROCHLORIDE",
"proprietary_name": "Bupropion hydrochloride",
"active_ingred_unit": "mg/1",
"application_number": "ANDA216800",
"marketing_category": "ANDA",
"nonproprietary_name": "Bupropion hydrochloride",
"start_marketing_date": "20230531",
"active_numerator_strength": "200"
}See everything about bupropion.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.